On this page
Thyrocare to exit radiology, sell Nueclear Healthcare stake for ₹141.4 crore
Our read
The divestment should modestly improve Thyrocare's strategic clarity and pathology-focused capital efficiency, but the financial upside depends on retaining bundled-diagnostics referral traffic through partnerships.
For operators
Thyrocare is streamlining operations around pathology by exiting radiology while retaining key Gurugram and Hyderabad lab premises to support its core network.
Watch
Transaction closing timeline and any conditions imposed by regulators or counterparties.
The report,
Thyrocare plans to sell its radiology subsidiary Nueclear Healthcare to Trovera for ₹141.4 crore, exiting diagnostic imaging to focus on pathology. It will acquire lab premises in Gurugram and Hyderabad from Nueclear for ₹20.59 crore.
- Total consideration for Nueclear Healthcare stake₹141.4 crore
- Cash consideration₹81.9 crore
- Consideration in Trovera CCPS₹59.5 crore
Reported figures
From the report. Source details below
| 42,500 Trovera CCPS at | ₹14,000 each |
|---|---|
| FY26 Nueclear turnover: | ₹44.62 crore |
| Thyrocare shares rose 3.22% to | ₹573.70 |
Also in the report
- ₹59.5 crore in Trovera CCPS
- ₹81.9 crore cash consideration
- 1.11 crore Nueclear Healthcare equity shares
- 4.5% fully diluted Trovera share capital
- 5.38% of Thyrocare consolidated turnover
- ₹83.55 crore Nueclear net worth
- 14.27% of Thyrocare consolidated net worth
Why it matters to operators
The transaction creates a cleaner pathology-led portfolio for Thyrocare while giving Trovera an entry into radiology through the acquisition of Nueclear Healthcare.
What to watch next
- Management disclosure on the sale's gain/loss, tax impact and planned use of proceeds.
- Pathology revenue growth and EBITDA margin trend after the radiology exit.
- Customer/referral retention in cities where Nueclear had meaningful imaging presence.
- Any ongoing commercial partnership between Thyrocare and Trovera/Nueclear.
- New pathology lab openings, automation investments, acquisitions or capital-return announcements.
Likely next moves
Our read of what comes next — analysis, not reported by the source.
- Complete regulatory and contractual approvals for the ₹141.4 crore Nueclear stake sale.
- Acquire and integrate the Gurugram and Hyderabad laboratory premises for ₹20.59 crore.
- Establish referral or service agreements with Trovera/Nueclear to retain access to imaging demand from Thyrocare's customer and physician network.
- Communicate revised segment economics, pathology growth priorities and treatment of divestment proceeds to investors.
The counter-case
The case against this reading — not reported by the source.
The exit may simplify the portfolio, but it also removes a potentially higher-growth adjacency and increases Thyrocare’s dependence on the mature, price-competitive pathology market. A business contributing 5.38% of turnover could have contributed disproportionately to future growth or cross-selling, and the ₹141.4 crore consideration cannot be judged attractive without profitability, asset values, debt, and historical investment data. Separately buying the Gurugram and Hyderabad premises for ₹20.59 crore raises questions about whether the transaction structure leaves Thyrocare with residual real-estate costs or operational obligations. Approval risk, transition disruption, employee/customer migration, and any stranded corporate costs could dilute the stated focus benefit.